132 related articles for article (PubMed ID: 37778252)
1. ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma.
Katoh I; Tsukinoki K; Hata RI; Kurata SI
Neoplasia; 2023 Nov; 45():100938. PubMed ID: 37778252
[TBL] [Abstract][Full Text] [Related]
2. DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma.
Pokorna Z; Hrabal V; Tichy V; Vojtesek B; Coates PJ
Front Oncol; 2022; 12():924354. PubMed ID: 35912167
[TBL] [Abstract][Full Text] [Related]
3. Complex and variable regulation of ΔNp63 and TAp63 by TGFβ has implications for the dynamics of squamous cell epithelial to mesenchymal transition.
Pokorná Z; Tylichová Z; Vojtesek B; Coates PJ
Sci Rep; 2024 Mar; 14(1):7304. PubMed ID: 38538801
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
5. ΔNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation.
Romano RA; Smalley K; Magraw C; Serna VA; Kurita T; Raghavan S; Sinha S
Development; 2012 Feb; 139(4):772-82. PubMed ID: 22274697
[TBL] [Abstract][Full Text] [Related]
6. Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.
Abbas HA; Bui NHB; Rajapakshe K; Wong J; Gunaratne P; Tsai KY; Coarfa C; Flores ER
Cancer Res; 2018 Jan; 78(2):451-462. PubMed ID: 29180475
[TBL] [Abstract][Full Text] [Related]
7. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells.
Petitjean A; Cavard C; Shi H; Tribollet V; Hainaut P; Caron de Fromentel C
Oncogene; 2005 Jan; 24(3):512-9. PubMed ID: 15543231
[TBL] [Abstract][Full Text] [Related]
8. Frequent alteration of p63 expression in human primary bladder carcinomas.
Park BJ; Lee SJ; Kim JI; Lee SJ; Lee CH; Chang SG; Park JH; Chi SG
Cancer Res; 2000 Jul; 60(13):3370-4. PubMed ID: 10910040
[TBL] [Abstract][Full Text] [Related]
9. Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma.
Herfs M; Hubert P; Suarez-Carmona M; Reschner A; Saussez S; Berx G; Savagner P; Boniver J; Delvenne P
Am J Pathol; 2010 Apr; 176(4):1941-9. PubMed ID: 20150431
[TBL] [Abstract][Full Text] [Related]
10. Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
Chen YK; Hsue SS; Lin LM
Int J Oral Maxillofac Surg; 2004 Jul; 33(5):493-7. PubMed ID: 15183414
[TBL] [Abstract][Full Text] [Related]
11. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis.
King KE; Ponnamperuma RM; Gerdes MJ; Tokino T; Yamashita T; Baker CC; Weinberg WC
Carcinogenesis; 2006 Jan; 27(1):53-63. PubMed ID: 16081516
[TBL] [Abstract][Full Text] [Related]
12. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
[TBL] [Abstract][Full Text] [Related]
13. The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63.
Helton ES; Zhu J; Chen X
J Biol Chem; 2006 Feb; 281(5):2533-42. PubMed ID: 16319057
[TBL] [Abstract][Full Text] [Related]
14. Expression of deltaNp63 in squamous cell carcinoma of the esophagus.
Morita M; Uramoto H; Nakata S; Ono K; Sugaya M; Yoshimatsu T; Oyama T; Hanagiri T; Sugio K; Yasumoto K
Anticancer Res; 2005; 25(5):3533-9. PubMed ID: 16101176
[TBL] [Abstract][Full Text] [Related]
15. Regulation of limbal keratinocyte proliferation and differentiation by TAp63 and DeltaNp63 transcription factors.
Wang DY; Cheng CC; Kao MH; Hsueh YJ; Ma DH; Chen JK
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3102-8. PubMed ID: 16123408
[TBL] [Abstract][Full Text] [Related]
16. TAp63 and DeltaNp63 in cancer and epidermal development.
Candi E; Dinsdale D; Rufini A; Salomoni P; Knight RA; Mueller M; Krammer PH; Melino G
Cell Cycle; 2007 Feb; 6(3):274-85. PubMed ID: 17264681
[TBL] [Abstract][Full Text] [Related]
17. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues.
Sethi I; Romano RA; Gluck C; Smalley K; Vojtesek B; Buck MJ; Sinha S
BMC Genomics; 2015 Aug; 16():584. PubMed ID: 26251276
[TBL] [Abstract][Full Text] [Related]
18. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
Nekulova M; Holcakova J; Nenutil R; Stratmann R; Bouchalova P; Müller P; Mouková L; Coates PJ; Vojtesek B
Virchows Arch; 2013 Sep; 463(3):415-25. PubMed ID: 23887585
[TBL] [Abstract][Full Text] [Related]
19. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice.
Candi E; Rufini A; Terrinoni A; Dinsdale D; Ranalli M; Paradisi A; De Laurenzi V; Spagnoli LG; Catani MV; Ramadan S; Knight RA; Melino G
Cell Death Differ; 2006 Jun; 13(6):1037-47. PubMed ID: 16601749
[TBL] [Abstract][Full Text] [Related]
20. Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
Alkhayyat R; Abbas A; Quinn CM; Rakha EA
Histopathology; 2024 Apr; 84(5):723-741. PubMed ID: 38012539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
